The underlying connection between NRAS mutations and KMT2A-SEPT6 and whether non-congenital KMT2A-SEPT6-positive AML patients all have NRAS mutations remain to be further studied in a larger cohort in the future. The gene discussed is SEPTIN6; the disease is acute myeloid leukemia.